Compare Bristol-Myers Squibb Co (BMY) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs FirstEnergy Corp. — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while FirstEnergy Corp. trades at $49.5 (market cap $28.01B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.2× FirstEnergy Corp.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | FE | |
|---|---|---|
Market Cap | $116.30B | $28.01B |
Sector | Health | Utilities |
52-Week High | $62.37 | $51.91 |
52-Week Low | $42.60 | $40.30 |
Enterprise Value | $152.24B | $56.02B |
Dividend Yield | 4.42% | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FirstEnergy Corp. (FE) trades at $48.43, up 1.06% on the day, with a bullish technical signal supported by moving averages. The stock shows steady revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, reflecting optimism around grid investments and data center demand. Recent news highlights FE's strategic positioning amid rising energy needs and infrastructure upgrades.
Outlook is positive due to strong fundamentals and growth initiatives, but risks include high debt levels and regulatory pressures. The stock offers potential upside from current levels, supported by earnings beats and institutional confidence, though investors should monitor cash flow trends and execution of capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
